This was the stock's fourth consecutive day of losses.

Regeneron Pharmaceuticals, Inc. REGN obtained positive opinion for its pipeline candidate linvoseltamab from the European ...

A lawsuit was filed for certain investors in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) shares. Investors who purchased shares of Regeneron ...

A gene therapy from Regeneron Pharmaceuticals Inc. improved hearing in nearly all deaf children in a clinical trial, results ...

The STEM Leadership Center, a Westchester County based nonprofit, in partnership with Regeneron Pharmaceuticals, Inc. and ...

Learn more about whether AbbVie Inc. or Regeneron Pharmaceuticals, Inc. is a better investment based on AAII's A+ Investor ...

The US Food and Drug Administration (FDA) has accepted for priority review the supplemental biologics license application (sBLA) for Dupixent (dupilumab) to treat adults with bullous pemphigoid (BP).

Regeneron Pharmaceuticals (NASDAQ ... (SNY), which was primarily driven by the sale of Dupixent. While the New York-based company managed to beat the consensus estimates by $43 million, I want ...

Regeneron Pharmaceuticals REGN has outperformed the market over the past 15 years by 12.37% on an annualized basis producing an average annual return of 24.38%. Currently, Regeneron ...

Regeneron Pharmaceuticals, Inc. discovers ... The company was incorporated in 1988 and is headquartered in Tarrytown, New York. Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes ...